Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 435

1.

Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, Krenning EP, de Herder WW.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717. doi: 10.1007/s00259-018-4158-1. Epub 2018 Sep 28.

2.

Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.

Lymperis E, Kaloudi A, Sallegger W, Bakker IL, Krenning EP, de Jong M, Maina T, Nock BA.

Bioconjug Chem. 2018 May 16;29(5):1774-1784. doi: 10.1021/acs.bioconjchem.8b00225. Epub 2018 Apr 30.

PMID:
29664606
3.

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Cwikla J, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169. doi: 10.1007/s00259-018-3967-6. Epub 2018 Feb 26.

PMID:
29484451
5.

Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM, de Herder WW, Krenning EP, Kwekkeboom DJ.

J Nucl Med. 2018 Mar;59(3):452-458. doi: 10.2967/jnumed.117.189712. Epub 2017 Aug 3.

PMID:
28775205
6.

In memoriam: Dirk J Kwekkeboom (1958-2017).

de Herder WW, Krenning EP, Krestin GP.

Endocr Relat Cancer. 2017 May 1;24(5):E1-E2. doi: 10.1530/ERC-17-0087. No abstract available.

PMID:
30390609
7.

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ.

Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.

8.

Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, Krenning EP, Kwekkeboom DJ.

Endocr Relat Cancer. 2017 May;24(5):243-251. doi: 10.1530/ERC-16-0524. Epub 2017 Mar 20.

PMID:
28320783
9.

Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.

Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.

J Nucl Med. 2017 Jan;58(1):75-80. doi: 10.2967/jnumed.116.178889. Epub 2016 Aug 4.

10.

(99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice.

Kaloudi A, Nock BA, Lymperis E, Krenning EP, de Jong M, Maina T.

Nucl Med Biol. 2016 Jun;43(6):347-54. doi: 10.1016/j.nucmedbio.2016.03.003. Epub 2016 Mar 19.

PMID:
27260775
11.

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate.

Bergsma H, Konijnenberg MW, van der Zwan WA, Kam BL, Teunissen JJ, Kooij PP, Mauff KA, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1802-11. doi: 10.1007/s00259-016-3382-9. Epub 2016 May 10.

12.

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.

Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP.

Semin Nucl Med. 2016 May;46(3):225-38. doi: 10.1053/j.semnuclmed.2015.12.003. Review.

PMID:
27067503
13.

Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation.

Kaloudi A, Nock BA, Lymperis E, Valkema R, Krenning EP, de Jong M, Maina T.

EJNMMI Res. 2016 Dec;6(1):15. doi: 10.1186/s13550-015-0158-3. Epub 2016 Feb 16.

14.

Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon.

Kaloudi A, Nock BA, Lymperis E, Krenning EP, de Jong M, Maina T.

Cancer Biother Radiopharm. 2016 Feb;31(1):20-8. doi: 10.1089/cbr.2015.1935.

PMID:
26844849
15.

Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.

Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):964-73. doi: 10.1007/s00259-015-3232-1. Epub 2015 Dec 2.

PMID:
26631238
16.

Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.

Kwekkeboom DJ, Krenning EP.

Hematol Oncol Clin North Am. 2016 Feb;30(1):179-91. doi: 10.1016/j.hoc.2015.09.009. Review.

PMID:
26614376
17.

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.

Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):839-51. doi: 10.1007/s00259-015-3250-z. Epub 2015 Nov 23.

PMID:
26596723
18.

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.

Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Franssen GJ, van Eijck CH, Krenning EP, Kwekkeboom DJ.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):453-63. doi: 10.1007/s00259-015-3193-4. Epub 2015 Sep 30.

19.

In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.

Kaloudi A, Nock BA, Lymperis E, Sallegger W, Krenning EP, de Jong M, Maina T.

Nucl Med Biol. 2015 Nov;42(11):824-32. doi: 10.1016/j.nucmedbio.2015.07.009. Epub 2015 Jul 29.

PMID:
26300210
20.

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.

van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, de Herder WW, Feelders RA, Bonsing BA, Brabander T, Krenning EP, Kwekkeboom DJ.

J Nucl Med. 2015 Nov;56(11):1647-53. doi: 10.2967/jnumed.115.158899. Epub 2015 Aug 13.

Supplemental Content

Loading ...
Support Center